Understanding the Role of Pembrolizumab in Melanoma Treatment

Pembrolizumab has established itself as a cornerstone of metastatic melanoma therapy by targeting the PD-1 pathway. While this immunotherapy has significantly improved survival, researchers continue to explore combination strategies. A recent phase II trial investigated whether adding carboplatin and paclitaxel (CP) to pembrolizumab could mirror the success seen in other cancers, such as non-small-cell lung cancer. However, the study findings suggest that for melanoma, more is not necessarily better.

In this trial, thirty patients with unresectable or metastatic melanoma received the combination therapy. The results showed an overall response rate (ORR) of 43% and a disease control rate (DCR) of 53%. While these figures are substantial, the median overall survival reached 23.8 months. Notably, the study concluded that the addition of chemotherapy did not provide a clear survival advantage over pembrolizumab monotherapy. Furthermore, the combination proved less tolerable, with 50% of participants experiencing Grade 3 or higher adverse events.

Biomarkers and Peripheral Inflammatory Signatures

One of the most valuable outcomes of this study was the identification of peripheral immune signals that correlate with clinical success. Identifying these markers helps clinicians understand which patients are most likely to benefit from pembrolizumab in melanoma treatment. Specifically, lower baseline levels of CCL3, IL-6, and IL-8 were associated with better survival and objective responses.

Additionally, the researchers observed that specific T-cell and NK-cell phenotypes played a role. A lower frequency of naive CD8 T cells and a higher proportion of mature NK cells at baseline were linked to better objective responses. Interestingly, following treatment, pro-inflammatory soluble factors increased across all patients, regardless of whether they responded to the therapy. These insights into the systemic immune environment provide a foundation for future personalized treatment approaches.

Clinical Implications for Oncology Practice

For oncologists, this trial reinforces the challenge of combining cytotoxic chemotherapy with checkpoint inhibitors in melanoma. Although chemotherapy is often used to rapidly reduce tumor burden, its synergistic effect with pembrolizumab appears limited in this setting. The increased toxicity profile suggests that monotherapy or other immunotherapy combinations might remain the preferred standard for most patients. Consequently, future research should focus on the peripheral signals identified in this study to refine patient selection and improve outcomes.

Frequently Asked Questions

Does adding chemotherapy to pembrolizumab improve melanoma survival?

No, this phase II trial indicated that adding carboplatin and paclitaxel to pembrolizumab did not result in a survival advantage and was less tolerable for patients than immunotherapy alone.

What biomarkers were associated with better outcomes in this trial?

Better clinical outcomes were associated with lower baseline levels of plasma CCL3, IL-6, and IL-8, as well as specific immune cell profiles like lower naive CD8 T cells and higher mature NK cells.

What was the safety profile of the combination therapy?

The safety profile was challenging, with 50% of patients experiencing Grade 3 or higher adverse events, making the combination less tolerable than standard pembrolizumab monotherapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Lambert C et al. A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. Oncoimmunology. 2026 Dec 31. doi: 10.1080/2162402X.2026.2631244. PMID: 41732954.

Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-2532. doi: 10.1056/NEJMoa1503093.

Hamid O, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology. 2019;30(4):582-588. doi: 10.1093/annonc/mdz011.